LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Kodu・Aktsiate loetelu・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Suletud

SektorTervishoid

43.42 3.95

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

43.58

Põhinäitajad
By Trading Economics
Sissetulek	7.3M -123M
Müük	3.7M 3.9M
Aktsiakasum	-1.29
Kasumimarginaal	-3,161.261
Töötajad	594
EBITDA	20M -122M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+107.22% upside

Turustatistika
By TradingEconomics
Turukapital	-140M 4.3B
Eelmine avamishind	39.47
Eelmine sulgemishind	43.42

Uudiste sentiment

By Acuity

42%

58%

187 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

30.39 / 33.46 Toetus ja vastupanu

Crinetics Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. mai 2026, 23:58 UTC

Tulu

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7. mai 2026, 22:57 UTC

Tulu

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7. mai 2026, 23:52 UTC

Tulu

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7. mai 2026, 23:45 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7. mai 2026, 23:39 UTC

Market Talk

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7. mai 2026, 23:28 UTC

Market Talk

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7. mai 2026, 23:11 UTC

Tulu

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7. mai 2026, 23:06 UTC

Tulu

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7. mai 2026, 23:05 UTC

Tulu

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7. mai 2026, 23:04 UTC

Tulu

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7. mai 2026, 23:03 UTC

Tulu

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7. mai 2026, 23:03 UTC

Tulu

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7. mai 2026, 23:02 UTC

Tulu

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7. mai 2026, 23:00 UTC

Market Talk

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7. mai 2026, 22:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. mai 2026, 22:45 UTC

Market Talk

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7. mai 2026, 22:42 UTC

Tulu

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7. mai 2026, 22:33 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7. mai 2026, 22:32 UTC

Tulu

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7. mai 2026, 22:31 UTC

Tulu

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7. mai 2026, 22:31 UTC

Tulu

Macquarie: 68% of FY Income From International >MQG.AU

7. mai 2026, 22:30 UTC

Tulu

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7. mai 2026, 22:30 UTC

Tulu

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7. mai 2026, 22:29 UTC

Tulu

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7. mai 2026, 22:28 UTC

Tulu

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7. mai 2026, 22:28 UTC

Tulu

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7. mai 2026, 22:27 UTC

Tulu

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7. mai 2026, 22:27 UTC

Tulu

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7. mai 2026, 22:26 UTC

Tulu

Macquarie to End Share Buyback Extended in November>MQG.AU

7. mai 2026, 22:25 UTC

Tulu

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Võrdlus sarnastega

Hinnamuutus

Crinetics Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

107.22% tõus

12 kuu keskmine prognoos

Keskmine 86.43 USD 107.22%

Kõrge 97 USD

Madal 67 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Crinetics Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Crinetics Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

30.39 / 33.46Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

187 / 347 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.